ESMO 2022

Endocrine response in eBC

Roadmap for the adjuvant setting

Long-term data on dose density therapy in chemotherapy

Dose-dense standard of care is the optimal care

Dose-dense therapy is beneficial for all patients

Immuntherapy only for low risk patients?

Hand cooling and compression both effective in preventing chemotherapy-induced peripheral neuropathy

My highlights of ESMO22

DD is the champion!

Reduction of peripheral neuropathy with taxane therapy

QoL and longterm toxicity

Simple and cheap surgical technique may impact survival in early breast cancer

Dose dense is better

Consolidating data from prospective studies

Il vincitore e’ il dose dense!!

Chłodzenie rąk i terapia kompresyjna skutecznie obniżają ryzyko neuropatii obwodowej po leczeniu taksanami

I miei punti salienti di ESMO22

Schéma dose-dense bénéfique pour toutes les patientes

Rosta i tania technika chirurgiczna może wpływać na czas przeżycia we wczesnym raku piersi

Datele trialurilor se consolideata

DATA: Still open questions on the optimal duration of extended adjuvant endocrine therapy? Greatest effect in the endocrine sensitive population. N+ higher risk. Contralateral disease with longer benefit

Dose-dense CT Efficacy confirmed in the Nodal+ ER+ population. Do all luminal patients benefit? What about secondary malignancies?

Status update - adjuvant IO. Are TILs prognostic?

How to deal with the negative SERD data?

Who needs Chemo? Who does not? Is OFS plus endocrine Therapy sufficient without prior Chemo? Response Assessment before surgery

Tailoring Adjuvant Therapy

Unmeet needs and my wishes for 2022!

ADC after ADC - is there any orientation?

Interim analysis shows promising data on Abema in the 1st Line

Endocrine-based therapy may prove more effective than chemo in “triple-positive” advanced breast cancer

HER2+ and still without chemotherapy

Another option for heavily pre-treated HR+ advanced breast cancer patients

SG is a novel treatment option for HR+/HER2- disease

Negative and yet positive?!

New data re-inforces SG as a new option pre-treated HR+/HER2- patients

Update on biomarkers on ADCs of the DAISY trial

CDK4/6i could be an option for selected ER+/HER2+ disease

VEX has no place in chemotherapy of metastatic breast cancer

My highlights of ESMO22

Sacituzumab govitecan for everybody!

New treatment option for heavily pre-treated patients with ER+ MBC

TROPiCS-02 highlights

Exciting data, but Phase 3 studies are needed

The third in the bunch

OS not significant, but re-assuring new data

More therapy options for patients with HR+, HER2+ disease

Survival benefit from SG in mBC

Survival benefit in endocrine sensitive patients

Discontinued development

I miei punti salienti di ESMO22

TROPiCS-02 highlights

Nuove opzioni di trattamento personalizzate per pazienti con tumore mammarioHR+/HER2+

Sacituzumab Govitecan: Un farmaco per tutte?

Nouvelles données des analyses expolratoires dans l’étude DAISY

Survie globale pas encore significative statistiquement mais données rassurantes

Sopravvivenza globale nello studio MONARCH3

Leczenie zaawansowanych raków „potrójnie dodatnich” oparte na hormonoterapii może okazać się bardziej skuteczne niż chemioterapia

Nouvelle option thérapeutique pour les patientes lourdement prétraitées RH+ HER2-

SG come nuova opzione di cura Per pazienti con tumore mammario HR+/HER2-

Monarch-3: strong OS Survival; DAWNA-2: PFS in line with existing CDK4/6i; monarcHER: a chemo-free treatment option

CDK4/6i plus Trastuzumab – a possible chemo-free option for triple positive patients?

Interim OS Data & PFS Update for Abemaciclib hint towards final consistent OS benefit. We need to focus on resistance drivers.

SERDs: equal PFS benefit vs. endocrine therapy; adjuvant data to be expected

SG confirms benefit in OS, PFS, ORR, QoL, the new 2nd line Standard of Care? What will be the treatment sequence? A European, US and Asian Perspective

ADC efficacy in perspective: SG overall survival benefit, efficacy comparable for HER2- and HER2low. ADC sequencing could become an option. We need data for earlier settings.

ADAURA Update - preventing relapse or just delaying it?

Liquid biopsy monitoring of EGFR-mutant lung cancer patients before and after surgery

Osimertinib - curing or delaying relapse?

Osimertinib stays standard adjuvant

Is OS really needed?

ADAURA revisited

Pollution and lung cancer - one mechanism revealed

Double IO + chemoradiotherapy - is it feasible in borderline resectable stage III NSCLC patients?

Window for treatment selection

INCREASE - to good to be true?

Long term follow-up of ADAURA trial

Concurrent preoperative IO/CRT in early lung cancer

Neoadjuvant strategies for PD-L1 < 1 %

Osimertinib: una cura o ritarda la ripresa di malattia?

Pollution et cancer du poumon - un mécanisme mis en évidence

ADAURA revisited

Dubbele immunotherapie plus chemoradiotherapie - is het haalbaar bij patiënten met borderline resectable stadium III NSCLC?

Eine Plattform für "take the winner"-Strategie

Osimertinib bleibt Standard adjuvant

Liquid biopsie monitoring van patiënten met een EGFR mutatie voor en na chirurgie

Langzeitdaten ADAURA

Important data on borderline resectable patients

DFS matters!

Can IO be discontinued?

Sotorasib vs. Docetaxel in mKRAS G12C

Long term follow-up of KEYNOTE-189 and KEYNOTE-407

Sotorasib - a new standard of care?

5-year update on 1st line chemoimmunotherapy

Atezolizumab better than vinorelbin in reduced performance status

HER2 - the next actionable mutation in lung cancer?

A new step in treatment of KRAS G12C mutant NSCLC

New immunotherapy options for pts. ineligible to 1st line platinum therapy

Pneumonitis and T-DXd

Cemiplimab beyond progression?

Sotorasib: sweet and sour results

The journey at KRAS G12C continues

If you don't look, vou don't find - once you found it, you'll treat it!

5 years of chemoimmunotherapy: solid grounded

5-year data on survival under immunotherapy

Duration of immunotherapy : Stop and go strategy for Nivo/Ipi

Immunotherapy in unfit population? Perhaps...

New therapy combination after progression on 1L osimertinib

Chemoimmunotherapy - improvement of survival after 5 years

One more brick in the KRAS G12C wall

Emerging IO mono options in the first line

Can we finally treat poor prognostic patients with immunotherapy?

Is shorter immunotherapy equally effective and less physically demanding?

Poseidon and STK11/KEAP

Preview on lung cancer highlights

DESTINY-Lung02 - better than the original?

Real-world data on Atezolizumab

Liquid biopsy monitoring in treatment decisions

Question about timing and duration of immunotherapy still unanswered

Induction chemoimmunotherapy in borderline resectability?

Un mattone in piu' nel muro del KRAS G12C

Atezo besser als Vino bei PS2-3

Données de vie réelle avec l’atezolizumab

Une nouvelle étape dans le traitement du CBNPC KRAS G12C muté

Kürzere Immuntherapie gleich effektiv aber weniger belastend?

Sotorasib vs. Docetaxel bei mKRAS G12C

Kann IO pausiert werden?

Cemiplimab beyond progression?

IO-IO neoadjuvant bei PD-L1 neg.

5 Jahre Chemo-Immuntherapie: starker Effekt

Chimio-immunothérapie - amélioration de la survie après 5 ans

Kunnen we eindelijk patiënten met een slechte prognose behandelen met immunotherapie?

Neue Therapiekombination in der Resistenz nach Osimertinib

Chemo-IO-Induktion bei grenzwertiger Resektabilität?

Les études incontournables à l’ESMO 2022

Una nueva opción de tratamiento con IO en pacientes no tributarios de 1L con platino

Durée de l'immunothérapie : stratégie Stop and Go pour l 'association Nivo/Ipi

Resultados Agridulces de Sotorasib

Liquid Biopsy Monitoring zur Therapiesteuerung

Die Reise bei KRAS G12C geht weiter

Pneumonitis und T-DXd

Poseidon und STK11/KEAP

Neue Option der IO-Therapie in der Erstlinie

5-Jahresüberleben mit Immuntherapie

Se non lo cerchi non lo troiv. Quando lo hai trovato, trattalo

Immunoterapia nella popolazione non fit: forse

Heterogenity in the genetic landscape - little progress in molecular alterations

A positive study! With a question mark?

Novel data and long-term efficacy of chemo-IO in mNSCLC

New strategies in immunotherapy

No value of IPI/Nivo in the adjuvant setting.

News in terms of adjuvant

Exciting data for high-risk patients: is this the start of a new era?

Adjuvant Immuntherapy in kidney cancer

New combo - triplet therapy for kidney cancer

Brief highlights about RCC & urothelial cancer from ESMO22

More questions being raised

Two negative studies question adjuvant approach in RCC

Place of triplet therapy

Immune-based peri-operative treatment in RCC: What went wrong?

Adjuvant CPI in kidney cancer – 2 phase III trials with novel insights!

Inmunoterapia adyuvante en el cancer renales

Μηνύματα από το ESMO22 για τον καρκίνο του νεφρού

Terapia triple para cancer renales

Tratamiento perioperatorio con immunoterapia en cáncer renal: Que ha fallado?

Immunomodulation in combination with checkpointinhibiton

Shedding light on TKI/Checkpointinhibitor combinations

Therapy combinations in RCC - what is the role of triplet therapy?

Adjuvant immunotherapy options in RCC - what do we learn from ESMO22 data for the adjuvant setting?

EV + pembrolizumab in cisplatin-ineligible patients

Brief highlights about RCC & urothelial cancer from ESMO22

EV + Pembro with excellent response rates

Μηνύματα από το ESMO22 για τον ουροθηλιακό καρκίνο

Biomarker exploration in urothelial cancer - finding the right assay for the right drug!

Adjuvant and neoadjuvant therapy approaches in urothelial cancer

Promising data, but beware of toxicity

ADCs - a possible therapeutic approach

Optimizing cabazitaxel chemotherapy

Further evaluation of PSA correlates

ADT + ENZA better choice than monotherapy

PSA at 8-months as a biomarker

Should intensification of ADT be considered in high-risk biochemically relapsed PC?

Length of hormone therapy after radiation

Update on the PROpel study

QoL data from ARASENS triplet therapy study mHRPC

Genetic testing before PARP therapy is useful

Biomarker data for better patients selection

Combination of olaparib leads to promising results

In older vulnerable - less is more

Triplet therapy with darolutamide in prostate cancer

IM arbiraterone decanoate might demonstrate superior therapeutic index and tolerability

Cabazitaxel better tolerated in elderly men

IO + PARP without benefit in the allcomer situation

Radicals - ADT & Radiotherapy

Livskvalitetsuppföljning i ARASENS studien

PSA efter 8 månader i PEACE-1 studien som biomarkör

Uppdatering i PROpel studien

Intimate partner violence in cancer patients

TILs - Fashion is the eternal return of the old

Novel approach von Biontech towards Cancer – game changing potential?!

Addition of CPI to Radiochemotherapy in LA-HNSCC?

IAP-inhibition – comming game changer in LA-HNSCC Radiochemotherapy

New group of substances for rare diseases